000163984 001__ 163984
000163984 005__ 20240717143409.0
000163984 0247_ $$2doi$$a10.3233/JPD-212787
000163984 0247_ $$2pmid$$apmid:35068416
000163984 0247_ $$2ISSN$$a1877-7171
000163984 0247_ $$2ISSN$$a1877-718X
000163984 0247_ $$2altmetric$$aaltmetric:121514917
000163984 037__ $$aDZNE-2022-00653
000163984 041__ $$aEnglish
000163984 082__ $$a610
000163984 1001_ $$aMichels, Jennifer$$b0
000163984 245__ $$aLong-Term Cognitive Decline Related to the Motor Phenotype in Parkinson's Disease.
000163984 260__ $$aAmsterdam$$bIOS Press$$c2022
000163984 3367_ $$2DRIVER$$aarticle
000163984 3367_ $$2DataCite$$aOutput Types/Journal article
000163984 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721219631_5185
000163984 3367_ $$2BibTeX$$aARTICLE
000163984 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163984 3367_ $$00$$2EndNote$$aJournal Article
000163984 520__ $$aParkinson's disease (PD) is associated with various non-motor symptoms, including cognitive deterioration.Here, we used data from the DEMPARK/LANDSCAPE cohort to describe the association between progression of cognitive profiles and the PD motor phenotypes: postural instability and gait disorder (PIGD), tremor-dominant (TR-D), and not-determined (ND).Demographic, clinical, and neuropsychological six-year longitudinal data of 711 PD-patients were included (age: M = 67.57; 67.4% males). We computed z-transformed composite scores for a priori defined cognitive domains. Analyses were controlled for age, gender, education, and disease duration. To minimize missing data and drop-outs, three-year follow-up data of 442 PD-patients was assessed with regard to the specific role of motor phenotype on cognitive decline using linear mixed modelling (age: M = 66.10; 68.6% males).Our study showed that in the course of the disease motor symptoms increased while MMSE and PANDA remained stable in all subgroups. After three-year follow-up, significant decline of overall cognitive performance for PIGD-patients were present and we found differences for motor phenotypes in attention (β= -0.08, SE = 0.003, p < 0.006) and memory functions showing that PIGD-patients deteriorate per months by -0.006 compared to the ND-group (SE = 0.003, p = 0.046). Furthermore, PIGD-patients experienced more often difficulties in daily living.Over a period of three years, we identified distinct neuropsychological progression patterns with respect to different PD motor phenotypes, with early executive deficits yielding to a more amnestic profile in the later course. Here, in particular PIGD-patients worsened over time compared to TR-D and ND-patients, highlighting the greater risk of dementia for this motor phenotype.
000163984 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163984 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000163984 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163984 650_7 $$2Other$$aCognitive decline
000163984 650_7 $$2Other$$aParkinson’s disease
000163984 650_7 $$2Other$$adementia
000163984 650_7 $$2Other$$alongitudinal
000163984 650_7 $$2Other$$amild cognitive impairment
000163984 650_7 $$2Other$$apostural instability and gait disorder
000163984 650_7 $$2Other$$aprogression
000163984 650_7 $$2Other$$atremor-dominant
000163984 650_2 $$2MeSH$$aCognitive Dysfunction: complications
000163984 650_2 $$2MeSH$$aFemale
000163984 650_2 $$2MeSH$$aGait Disorders, Neurologic: diagnosis
000163984 650_2 $$2MeSH$$aHumans
000163984 650_2 $$2MeSH$$aMale
000163984 650_2 $$2MeSH$$aNeuropsychological Tests
000163984 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000163984 650_2 $$2MeSH$$aPhenotype
000163984 650_2 $$2MeSH$$aPostural Balance
000163984 650_2 $$2MeSH$$aTremor: diagnosis
000163984 7001_ $$avan der Wurp, Hendrik$$b1
000163984 7001_ $$aKalbe, Elke$$b2
000163984 7001_ $$aRehberg, Sarah$$b3
000163984 7001_ $$0P:(DE-2719)9000306$$aStorch, Alexander$$b4
000163984 7001_ $$0P:(DE-2719)2812121$$aLinse, Katharina$$b5
000163984 7001_ $$0P:(DE-HGF)0$$aSchneider, Christine$$b6
000163984 7001_ $$0P:(DE-2719)2810662$$aGräber, Susanne$$b7
000163984 7001_ $$0P:(DE-2719)2000059$$aBerg, Daniela$$b8
000163984 7001_ $$aDams, Judith$$b9
000163984 7001_ $$aBalzer-Geldsetzer, Monika$$b10
000163984 7001_ $$aHilker-Roggendorf, Rüdiger$$b11
000163984 7001_ $$aOberschmidt, Carola$$b12
000163984 7001_ $$aBaudrexel, Simon$$b13
000163984 7001_ $$aWitt, Karsten$$b14
000163984 7001_ $$aSchmidt, Nele$$b15
000163984 7001_ $$0P:(DE-2719)9000934$$aDeuschl, Günther$$b16
000163984 7001_ $$0P:(DE-2719)9001340$$aMollenhauer, Brit$$b17
000163984 7001_ $$aTrenkwalder, Claudia$$b18
000163984 7001_ $$0P:(DE-2719)2109499$$aLiepelt-Scarfone, Inga$$b19
000163984 7001_ $$0P:(DE-2719)2811324$$aSpottke, Annika$$b20
000163984 7001_ $$0P:(DE-2719)2810395$$aRoeske, Sandra$$b21
000163984 7001_ $$0P:(DE-2719)2000056$$aWüllner, Ullrich$$b22
000163984 7001_ $$aWittchen, Hans-Ulrich$$b23
000163984 7001_ $$aRiedel, Oliver$$b24
000163984 7001_ $$0P:(DE-2719)9001967$$aKassubek, Jan$$b25
000163984 7001_ $$0P:(DE-2719)9000057$$aDodel, Richard$$b26
000163984 7001_ $$aSchulz, Jörg Bernhard$$b27
000163984 7001_ $$aCosta, Ana Sofia$$b28
000163984 7001_ $$aReetz, Kathrin$$b29
000163984 773__ $$0PERI:(DE-600)2599550-9$$a10.3233/JPD-212787$$gVol. 12, no. 3, p. 905 - 916$$n3$$p905 - 916$$tJournal of Parkinson's Disease$$v12$$x1877-7171$$y2022
000163984 8564_ $$uhttps://pub.dzne.de/record/163984/files/DZNE-2022-00653_Restricted.pdf
000163984 8564_ $$uhttps://pub.dzne.de/record/163984/files/DZNE-2022-00653_Restricted.pdf?subformat=pdfa$$xpdfa
000163984 909CO $$ooai:pub.dzne.de:163984$$pVDB
000163984 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000306$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000163984 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812121$$aExternal Institute$$b5$$kExtern
000163984 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810662$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000163984 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000059$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000163984 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000934$$aExternal Institute$$b16$$kExtern
000163984 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001340$$aExternal Institute$$b17$$kExtern
000163984 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2109499$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b19$$kDZNE
000163984 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811324$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000163984 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810395$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b21$$kDZNE
000163984 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000056$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b22$$kDZNE
000163984 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001967$$aExternal Institute$$b25$$kExtern
000163984 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000057$$aExternal Institute$$b26$$kExtern
000163984 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163984 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000163984 9141_ $$y2022
000163984 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000163984 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000163984 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000163984 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000163984 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000163984 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000163984 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PARKINSON DIS : 2021$$d2022-11-25
000163984 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-25
000163984 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-25
000163984 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ PARKINSON DIS : 2021$$d2022-11-25
000163984 9201_ $$0I:(DE-2719)5000014$$kAG Storch$$lNon-Motor Symptoms in Parkinson's disease$$x0
000163984 9201_ $$0I:(DE-2719)1240005$$kCore ICRU$$lCore ICRU$$x1
000163984 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x2
000163984 9201_ $$0I:(DE-2719)5000055$$kAG Berg ; AG Berg$$lParkinson's Disease Genetics$$x3
000163984 9201_ $$0I:(DE-2719)1011001$$kAG Klockgether$$lPatient Studies$$x4
000163984 9201_ $$0I:(DE-2719)1011201$$kAG Wagner$$lNeuropsychology$$x5
000163984 9201_ $$0I:(DE-2719)1011302$$kAG Wüllner$$lBiomarker Parkinson's Disease$$x6
000163984 980__ $$ajournal
000163984 980__ $$aVDB
000163984 980__ $$aI:(DE-2719)5000014
000163984 980__ $$aI:(DE-2719)1240005
000163984 980__ $$aI:(DE-2719)1210001
000163984 980__ $$aI:(DE-2719)5000055
000163984 980__ $$aI:(DE-2719)1011001
000163984 980__ $$aI:(DE-2719)1011201
000163984 980__ $$aI:(DE-2719)1011302
000163984 980__ $$aUNRESTRICTED